featured
Real-World Incidence and Management of AEs in Patients With HR+, HER2− Metastatic Breast Cancer Receiving CDK4/6 Inhibitors
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Current Medical Research and Opinion
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Real world incidence and management of adverse events in patients with HR+, HER2- metastatic breast cancer receiving CDK4 and 6 inhibitors in a United States community setting
Curr Med Res Opin 2022 May 13;[EPub Ahead of Print], GL Price, L Sudharshan, P Ryan, J Rajkumar, KM Sheffield, E Nash Smyth, C Morato Guimaraes, S Rybowski, G Cuyun Carter, WG Gathirua-Mwangi, YJ HuangFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.